Lakeside Advisors INC. Lowers Holdings in Eli Lilly and Company (NYSE:LLY)

Lakeside Advisors INC. decreased its position in Eli Lilly and Company (NYSE:LLY) by 6.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 677 shares of the company’s stock after selling 50 shares during the period. Lakeside Advisors INC.’s holdings in Eli Lilly and Company were worth $395,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Latitude Advisors LLC boosted its position in Eli Lilly and Company by 4.9% during the 4th quarter. Latitude Advisors LLC now owns 1,274 shares of the company’s stock valued at $743,000 after acquiring an additional 60 shares in the last quarter. Tyche Wealth Partners LLC bought a new stake in Eli Lilly and Company during the 4th quarter valued at $1,799,000. Arbor Trust Wealth Advisors LLC boosted its position in Eli Lilly and Company by 7.6% during the 4th quarter. Arbor Trust Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $741,000 after acquiring an additional 90 shares in the last quarter. HealthInvest Partners AB bought a new stake in Eli Lilly and Company during the 4th quarter valued at $9,213,000. Finally, Avior Wealth Management LLC boosted its position in Eli Lilly and Company by 1.5% during the 4th quarter. Avior Wealth Management LLC now owns 4,935 shares of the company’s stock valued at $2,877,000 after acquiring an additional 72 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded down $4.03 during trading on Wednesday, reaching $746.74. 2,569,799 shares of the company’s stock traded hands, compared to its average volume of 2,215,511. Eli Lilly and Company has a fifty-two week low of $367.35 and a fifty-two week high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a market cap of $709.52 billion, a PE ratio of 128.72, a P/E/G ratio of 1.64 and a beta of 0.34. The company has a 50-day simple moving average of $763.51 and a 200-day simple moving average of $657.01.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period last year, the firm earned $2.09 EPS. The company’s quarterly revenue was up 28.1% on a year-over-year basis. As a group, analysts predict that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent research reports. Truist Financial reaffirmed a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a report on Monday. The Goldman Sachs Group increased their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Finally, Citigroup increased their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.